Our findings may provide an insight into better understanding of the underlying immune-pathological mechanism in CVB3-induced myocarditis, and constitute the first preclinical data indicating that A20 can control CVB3-induced myocarditis. The gene discussed is TNFAIP3; the disease is myocarditis.